色素減退症治療市場 - 依治療類型（藥物{皮質類固醇、黑色素細胞刺激激素}、手術{雷射治療、光療}）、疾病適應症（白斑症、白化症）、全球預測 2024 - 2032

Hypopigmentation Disorder Treatment Market - By Treatment Type (Drugs {Corticosteroids, Melanocyte-Stimulating Hormone}, Procedures {Laser treatment, Phototherapy}), Disease Indication (Vitiligo, Albinism), Global Forecast 2024 - 2032

出版日期: 2024年03月19日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於人們對皮膚健康的認知不斷提高以及白斑症和白化病等皮膚病患病率的上升，2024年至2032年間色素沉著不足疾病治療市場規模的複合年成長率可能達到6.1%。根據全球白斑症基金會 (GVF) 的資料，全球約有 7,000 萬人患有白斑症。醫療技術和皮膚病學研究的不斷進步也大大擴大了色素沉著不足疾病的治療選擇。

最近，雷射療法、光療和植皮技術等創新治療方式的採用已取得了重大進展。製藥公司和研究機構之間為開發新型治療干預措施而加強的合作正在導致治療選擇的多樣化，進一步促進了產業的成長。

色素減退症治療行業根據治療類型、疾病適應症和地區進行分類。

就治療類型而言，預計到 2032 年，手術領域的市場規模將顯著成長，這得益於雷射治療、植皮和微色素沉著技術等皮膚科手術的進步。患者對微創手術的日益偏好導致美容治療的接受度不斷提高。配備最先進設備和熟練醫療保健專業人員的皮膚科診所和整容手術中心數量不斷擴大，預計將推動該細分市場的成長。

根據疾病跡象，白斑症領域的色素減退症治療市場將在 2032 年之前擴大。醫學研究的快速進步導致了專門針對白斑症的新療法的開發，包括局部治療。醫療保健組織和倡導團體不斷採取措施減少與這種疾病相關的恥辱感，這將有利於市場成長。

由於人口眾多、可支配收入增加以及醫療保健支出增加，亞太地區色素減退症治療行業將在 2024 年至 2032 年間出現良好成長。在亞太地區的一些國家，白斑和黃褐斑等皮膚病的盛行率特別高。醫療技術和醫療保健基礎設施的不斷進步，特別是在中國、日本和韓國等國家，將有助於先進治療方式的可及性和採用，從而刺激區域市場的成長。

產業生態系統分析
產業影響力
- 成長動力
  - 擴大採用先進的皮膚護理程序
  - 色素沉著不足疾病的盛行率不斷增加
  - 皮膚科治療支出不斷增加
  - 年輕人對皮膚健康的認知不斷提高
- 產業陷阱與挑戰
  - 整容手術費用高
成長潛力分析
監管環境
管道分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按治療類型，2018 - 2032 年

主要趨勢
藥品
- 按類型
  - 皮質類固醇
  - 黑色素細胞刺激激素
  - 其他藥品
- 依給藥途徑
  - 口服
  - 專題
  - 其他給藥途徑
- 按配銷通路
  - 醫院藥房
  - 零售藥局
  - 網路藥局
程式
- 按類型
  - 雷射治療
  - 光療
  - 微晶煥膚術
  - 其他手續
- 按最終用戶
  - 醫院
  - 皮膚科診所
  - 美容中心
  - 其他最終用戶

第 6 章：市場估計與預測：按疾病適應症，2018 - 2032 年

主要趨勢
白斑
白化病
其他疾病適應症

第 7 章：市場估計與預測：按地區分類，2018 年 - 2032 年

主要動向：按地區
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 8 章：公司簡介

AbbVie Inc.
Aclaris Therapeutics, Inc.
Bayer AG
Candela Corporation
Galderma
Incyte
Novartis AG
Pfizer Inc.
Pierre Fabre group
Shiseido Company Limited
UNIZA Group

簡介目錄

Product Code: 8575

Hypopigmentation disorder treatment market size is likely to register 6.1% CAGR between 2024 to 2032, driven by increasing awareness about skin health and the rising prevalence of skin conditions, such as vitiligo and albinism. As per data from the Global Vitiligo Foundation (GVF), around 70 million people globally suffer from vitiligo. Growing advancements in medical technology and dermatological research are also contributing significantly to the expansion of treatment options available for hypopigmentation disorders.

Lately, the adoption of innovative treatment modalities like laser therapy, phototherapy, and skin grafting techniques has picked significant ground . Rising collaborations between pharmaceutical companies and research institutions for the development of novel therapeutic interventions are leading to the diversification of treatment options, further adding to the industry growth.

The hypopigmentation disorder treatment industry is classified on the basis of treatment type, diseases indication and region.

In terms of treatment type, the market size from the procedures segment is anticipated to witness notable growth rate through 2032, favored by the advancements in dermatological procedures, such as laser therapy, skin grafting, and micropigmentation techniques. The increasing preference for minimally invasive procedures among patients has resulted in the growing acceptance of aesthetic treatments. The expanding base of dermatology clinics and cosmetic surgery centers equipped with state-of-the-art equipment and skilled healthcare professionals is expected to drive the segment growth.

Based on disease indication, the hypopigmentation disorder treatment market from the vitiligo segment will expand through 2032. This is driven by the increasing prevalence of vitiligo worldwide, coupled with the growing awareness about the condition. Rapid advancements in medical research have led to the development of novel therapies specifically targeting vitiligo, including topical treatments. Rising initiatives by healthcare organizations and advocacy groups to reduce stigma associated with the condition will favor the market growth.

Asia Pacific hypopigmentation disorder treatment industry will witness decent growth between 2024-2032, attributed to the large population along with rising disposable incomes, and increasing healthcare expenditures. The prevalence of skin conditions, such as vitiligo and melasma is notably high in several countries across the APAC. Growing advancements in medical technology and healthcare infrastructure, particularly in countries like China, Japan, and South Korea, will contribute to the accessibility and adoption of advanced treatment modalities, subsequently stimulating the regional market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing adoption of advanced skin care procedures
  - 3.2.1.2 Increasing prevalence of hypopigmentation disorders
  - 3.2.1.3 Growing expenditure on dermatological treatments
  - 3.2.1.4 Rising awareness regarding skin health among younger population
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of cosmetic procedures
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
- 3.6.1 Supplier power
- 3.6.2 Buyer power
- 3.6.3 Threat of new entrants
- 3.6.4 Threat of substitutes
- 3.6.5 Industry rivalry
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Drugs
- 5.2.1 By type
  - 5.2.1.1 Corticosteroids
  - 5.2.1.2 Melanocyte-stimulating hormone
  - 5.2.1.3 Other drugs
- 5.2.2 By route of administration
  - 5.2.2.1 Oral
  - 5.2.2.2 Topical
  - 5.2.2.3 Other routes of administrations
- 5.2.3 By distribution channel
  - 5.2.3.1 Hospital pharmacies
  - 5.2.3.2 Retail pharmacies
  - 5.2.3.3 Online pharmacies
5.3 Procedures
- 5.3.1 By type
  - 5.3.1.1 Laser treatment
  - 5.3.1.2 Phototherapy
  - 5.3.1.3 Microdermabrasion
  - 5.3.1.4 Other procedures
- 5.3.2 By end-user
  - 5.3.2.1 Hospitals
  - 5.3.2.2 Dermatology clinics
  - 5.3.2.3 Aesthetic centers
  - 5.3.2.4 Other end-users

Chapter 6 Market Estimates and Forecast, By Disease Indication, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Vitiligo
6.3 Albinism
6.4 Other disease indications

Chapter 7 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

7.1 Key trends, by region
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
7.3 Europe
- 7.3.1 Germany
- 7.3.2 UK
- 7.3.3 France
- 7.3.4 Spain
- 7.3.5 Italy
- 7.3.6 Rest of Europe
7.4 Asia Pacific
- 7.4.1 Japan
- 7.4.2 China
- 7.4.3 India
- 7.4.4 Australia
- 7.4.5 Rest of Asia Pacific
7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Mexico
- 7.5.3 Rest of Latin America
7.6 Middle East and Africa
- 7.6.1 South Africa
- 7.6.2 Saudi Arabia
- 7.6.3 Rest of Middle East and Africa